-National Securities Exchange Report the Removal from listing and reg. of matured,redeemed or retired securities (25)
21 Octubre 2008 - 7:53AM
Edgar (US Regulatory)
OMB
APPROVAL
|
OMB
Number:
|
Expires:
|
Estimated
average burden
|
hours per response . . . . . .
|
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
25
NOTIFICATION
OF REMOVAL FROM LISTING AND/OR
REGISTRATION
UNDER SECTION 12(b) OF THE
SECURITIES
EXCHANGE ACT OF 1934.
Commission
File Number
_1-32001_
Lorus Therapeutics Inc.-NYSE
Alternext
(Exact
name of Issuer as specified in its charter, and name of Exchange where security
is listed and/or registered)
____
2 Meridian Road, Toronto,
Ontario, Canada M9W 4Z7 416-798-1200
___
(Address,
including zip code, and telephone number, including area code, of Issuer’s
principal executive offices)
Common
Shares
(Description
of class of securities)
Please
place an X in the box to designate the rule provision relied upon to strike the
class of securities from listing and registration:
o
|
|
17
CFR 240.12d2-2(a)(1)
|
|
|
o
|
|
17
CFR 240.12d2-2(a)(2)
|
|
|
o
|
|
17
CFR 240.12d2-2(a)(3)
|
|
|
o
|
|
17
CFR 240.12d2-2(a)(4)
|
o
Pursuant to 17 CFR
240.12d2-2(b), the Exchange has complied with its rules to strike the class of
securities from listing and/or withdraw registration on the Exchange.
1
X
|
Pursuant
to 17 CFR 240.12d2-2(c), the Issuer has complied with the rules of the
Exchange and the requirements of 17 CFR 240.12d2-2(c) governing the
voluntary withdrawal of the class of securities from listing and
registration on the Exchange.
|
Pursuant
to the requirements of the Securities Exchange Act of 1934, Lorus Therapeutics
Inc.certifies that it has reasonable grounds to believe that it meets all of the
requirements for filing the Form 25 and has caused this notification to be
signed on its behalf by the undersigned duly authorized person.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
October
21, 2008
|
|
By
|
|
/s/
Elizabeth Williams
|
|
|
|
Director
of Finance, Acting
Chief Financial Officer
|
Date
|
|
|
|
Elizabeth
Williams
|
|
|
|
Title
|
1
Form 25 and attached
Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as
applicable. See General Instructions.
|
|
|
SEC1654(03-06)
|
|
Persons
who respond to the collection of information contained in this form are
not required to respond unless the form displays a currently valid OMB
control number.
|
Lorus Therapeutics (AMEX:LRP)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024
Lorus Therapeutics (AMEX:LRP)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024
Real-Time news about Lorus Therapeutics, (New) (American Stock Exchange): 0 recent articles
Más de Artículos de Noticias